This bill tasks the Secretary of Labor, through OSHA, with developing workplace materials on opioid overdose reversal medication and training. It splits the response: guidance for private-sector employers and compulsory regulations for Federal agencies.
For employers the guidance is explicitly non‑binding; for the Federal Government the bill requires agencies to obtain and keep reversal medication on site and to provide yearly training for employees. The measure sets a single federal expectation that workplaces should be prepared to respond to opioid overdoses, while leaving detailed adoption decisions to employers outside the federal executive branch.
At a Glance
What It Does
The legislation directs Labor/OSHA to produce guidance for employers about obtaining and maintaining opioid overdose reversal medication and to require annual employee training. It also obligates the Secretary to issue binding regulations that force Federal agencies to keep such medication available and to train staff annually.
Who It Affects
Federal executive agencies and their workforce are directly regulated; private employers receive guidance but no new legal duty under this bill. Occupational health managers, HR teams, federal procurement officers, and workplace trainers will be the primary operational contacts.
Why It Matters
The bill creates a clear federal baseline for overdose preparedness at government workplaces and signals best practices for the private sector. By making the rules binding for agencies, it will drive procurement, storage, and training decisions across the federal executive branch and may influence private employers and contractors.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill has two distinct tracks. For non‑federal employers it requires OSHA to prepare and publish non‑mandatory guidance on how workplaces can obtain and maintain opioid overdose reversal medication and on training employees to use it.
That guidance is advisory — it does not itself create an enforceable duty — but it is intended to provide practical steps employers can adopt if they choose to make reversal medication part of their emergency response.
For federal agencies the bill takes a firmer approach: the Secretary must issue regulations that require each agency to acquire and keep opioid overdose reversal medication on hand and to train employees about its use at least once a year. The statute expressly reaches all agencies and instrumentality of the federal government, and it names the Veterans Health Administration as covered, removing any statutory uncertainty about that agency’s inclusion.The Secretary must act through OSHA to produce both the guidance and the regulations.
The bill sets a clear administrative path — guidance for the private sector and rulemaking for federal entities — but it does not specify standards for medication type, storage conditions, recordkeeping, or penalties for noncompliance by agencies. It likewise does not appropriate funds or create a central procurement mechanism, leaving acquisition and training logistics to agency implementing documents and budgets.Because the measure is narrowly focused on acquiring medication and providing annual training, it interacts with wider workplace safety and public health regimes.
Agencies will need to fold these requirements into existing emergency response plans, bargaining obligations where applicable, and federal procurement rules. Private employers may use the OSHA guidance to shape internal policies, insurance protocols, and relationships with local emergency medical services.
The Five Things You Need to Know
The bill requires the Secretary of Labor, acting through OSHA, to issue both non‑mandatory employer guidance and mandatory regulations for Federal agencies.
It mandates that Federal agencies acquire and maintain opioid overdose reversal medication and train employees annually on its use.
The statute uses a 270‑day deadline: the Secretary must issue the guidance and the regulations no later than 270 days after enactment.
In defining who is covered, the bill adopts the OSHA definition of 'employer' but explicitly excludes the United States Postal Service from the employer guidance provision.
The provision defining 'Federal agency' expressly includes the Veterans Health Administration, 'notwithstanding' 38 U.S.C. 7425(b), removing a statutory barrier to covering that entity.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the Act two names: the Workplace Overdose Reversal Kits to Save Lives Act and the WORK to Save Lives Act. This is the bill’s caption and has no operational effect, but it signals legislative intent and frames the measure around workplace lifesaving interventions.
Non‑mandatory employer guidance via OSHA
Directs the Secretary of Labor, through OSHA, to publish advisory material for employers about acquiring/maintaining opioid overdose reversal medication and providing annual training. The provision imports the OSHA definition of 'employer' (so it applies broadly across private businesses) but carves out the U.S. Postal Service from this guidance requirement. Practically, OSHA will need to translate clinical and procurement questions into workplace steps; because the guidance is nonbinding, enforcement will be limited to persuasion, standard setting, and potential influence on private litigation or insurance practices.
Mandatory regulations for Federal agencies
Requires OSHA to promulgate regulations that obligate every Federal agency and instrumentality to obtain and maintain opioid reversal medication and to train employees annually on its use. The statute explicitly covers the Veterans Health Administration despite statutory text that might otherwise exclude it. This provision creates direct, binding obligations on executive branch entities and will require agencies to incorporate procurement, storage, training, and possibly medical oversight into their internal policies and budgets.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal employees and contractors — they'll work at sites required to keep reversal medication and to receive annual training, increasing on‑site emergency response capacity.
- People at risk of overdose who interact with federal workplaces — wider naloxone availability could reduce fatal overdoses in and around federal facilities.
- Workplace health and safety specialists and training providers — agencies and employers seeking materials and training will create demand for curricula, instructor time, and consulting services.
Who Bears the Cost
- Federal agencies — must fund procurement of medication, storage solutions, recordkeeping, and yearly training programs; costs will come from existing budgets unless separately appropriated.
- Private employers who choose to follow OSHA’s guidance — while non‑mandatory, adopting the guidance will create procurement and training expenses and administrative overhead.
- OSHA and the Department of Labor — must allocate staff time to produce guidance and to complete rulemaking for agencies within the statutory deadline, diverting administrative resources.
Key Issues
The Core Tension
The central dilemma is between maximizing immediate access to a proven lifesaving intervention and imposing new operational costs and administrative burdens without dedicated funding or technical standards: the bill accelerates access for federal workplaces and nudges the private sector, but it shifts procurement, training, and implementation burdens onto agencies and employers who must absorb the costs and resolve technical details themselves.
The bill establishes a federal expectation for workplace overdose preparedness but leaves key implementation choices unanswered. It does not define what counts as 'opioid overdose reversal medication' (the clinical form, dosing, shelf‑life, or approved products), nor does it require specific storage or documentation standards.
Those gaps mean agencies and employers must make judgment calls or wait for OSHA’s implementing materials, which could vary in detail. The statute also does not supply funds for agencies to buy medication or run training, so compliance depends on internal budgetary prioritization and may compete with other agency needs.
Another unresolved issue is enforcement. The guidance to private employers is expressly nonbinding, so uptake will depend on voluntary adoption, liability considerations, contract terms, and state/local rules.
For federal agencies the bill contemplates binding regulations, but it does not specify enforcement mechanisms or penalties for agency noncompliance; oversight may fall to internal inspectors general, Congress, or administrative orders. Finally, the bill reaches the VHA explicitly, but coordination with clinical operations at VHA facilities — where clinical staff may already manage naloxone distribution — will require careful interface between occupational safety rules and existing healthcare protocols.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.